Recent advances and challenges of bispecific antibodies in solid tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances and challenges of bispecific antibodies in solid tumors
Authors
Keywords
-
Journal
Experimental Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-18
DOI
10.1186/s40164-021-00250-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
- (2021) Matthew D. Hellmann et al. CLINICAL CANCER RESEARCH
- The PSMA Targeting Half-Life Extended BiTE® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer
- (2021) Petra Deegen et al. CLINICAL CANCER RESEARCH
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond
- (2021) Jones T. Nauseef et al. European Urology Focus
- Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
- (2021) Joost Neijssen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China
- (2021) Zhonghan Zhang et al. Journal of Hematology & Oncology
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
- (2020) Cris Kamperschroer et al. Journal of Immunotoxicology
- A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma
- (2020) Lin Yu et al. CANCER BIOLOGY & THERAPY
- Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
- (2020) Heliang Li et al. Cellular & Molecular Immunology
- Epidemiology of Hepatocellular Carcinoma
- (2020) Katherine A. McGlynn et al. HEPATOLOGY
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
- (2020) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
- (2020) Yuexian Zhou et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
- (2020) Margaux Lejeune et al. Frontiers in Immunology
- Current View on EpCAM Structural Biology
- (2020) Aljaž Gaber et al. Cells
- Clinical Significances of Positive Postoperative Serum CEA and Post-preoperative CEA Increment in Stage II and III Colorectal Cancer: A Multicenter Retrospective Study
- (2020) Weiqiang You et al. Frontiers in Oncology
- Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?
- (2020) Olivier Gires et al. CANCER AND METASTASIS REVIEWS
- Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis
- (2020) Smruthi Vijayaraghavan et al. MOLECULAR CANCER THERAPEUTICS
- 609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
- (2020) B. Tran et al. ANNALS OF ONCOLOGY
- Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
- (2020) Helen Kotanides et al. Cancer Immunology Research
- EpCAM as Modulator of Tissue Plasticity
- (2020) François Fagotto Cells
- Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials
- (2020) Seyed Samad Hosseini et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- NOTCH signalling in ovarian cancer angiogenesis
- (2020) Jose Alejandro Perez-Fidalgo et al. Annals of Translational Medicine
- Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
- (2020) Horst-Dieter Hummel et al. Immunotherapy
- 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
- (2019) Kirsten L. Moek et al. CLINICAL CANCER RESEARCH
- Taking a "BiTE out of ALL" - Blinautmomab approval for MRD positive ALL
- (2019) Emily Curran et al. BLOOD
- Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
- (2019) Horst-Dieter Hummel et al. JOURNAL OF CLINICAL ONCOLOGY
- MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
- (2019) Qiming Wang et al. Journal of Hematology & Oncology
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy
- (2019) Yoshika Iwata et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
- (2019) Jeffrey D. Bradley et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific antibodies in cancer immunotherapy
- (2019) Christoph Rader CURRENT OPINION IN BIOTECHNOLOGY
- Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines
- (2018) MAKOTO KUBO et al. ANTICANCER RESEARCH
- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
- (2018) Maren Knödler et al. BRITISH JOURNAL OF CANCER
- Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
- (2018) Aurelia H. M. de Vries Schultink et al. INVESTIGATIONAL NEW DRUGS
- Development of MGD007, a gpA33 x CD3 bispecific DART® protein for T-cell immunotherapy of metastatic colorectal cancer
- (2018) Paul A Moore et al. MOLECULAR CANCER THERAPEUTICS
- Bispecific antibodies for cancer therapy: A review
- (2018) Anuradha Krishnamurthy et al. PHARMACOLOGY & THERAPEUTICS
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
- (2018) Z. Wu et al. PHARMACOLOGY & THERAPEUTICS
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
- (2018) Alexander Drilon et al. Cancer Discovery
- A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
- (2018) Maxim Kebenko et al. OncoImmunology
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors
- (2018) Antonio Jimeno et al. INVESTIGATIONAL NEW DRUGS
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Cancer: Bispecific antibody directs T cells to solid tumours
- (2017) Megan Cully NATURE REVIEWS DRUG DISCOVERY
- Engineering bispecific antibodies with defined chain pairing
- (2017) Simon Krah et al. New Biotechnology
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer
- (2017) Haruhiko Nakamura et al. SURGERY TODAY
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
- (2017) Andres Lopez-Albaitero et al. OncoImmunology
- A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
- (2016) N. Haense et al. BMC CANCER
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
- (2016) U. Haberkorn et al. CLINICAL CANCER RESEARCH
- A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
- (2016) M. Bacac et al. CLINICAL CANCER RESEARCH
- In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
- (2016) S. Lehmann et al. CLINICAL CANCER RESEARCH
- Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas
- (2016) Michael Pishvaian et al. Clinical Colorectal Cancer
- Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer
- (2016) Martin Barrio et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
- (2016) Jie Huang et al. MOLECULAR CANCER THERAPEUTICS
- A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
- (2015) Morten Mau-Sørensen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Bispecific antibody platforms for cancer immunotherapy
- (2014) Roeland Lameris et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
- (2014) Michael D Oberst et al. mAbs
- Antibody Fc: Linking Adaptive and Innate Immunity
- (2014) Janice M. Reichert mAbs
- HER3, serious partner in crime
- (2014) Arjan Kol et al. PHARMACOLOGY & THERAPEUTICS
- On the Antiquity of Cancer: Evidence for Metastatic Carcinoma in a Young Man from Ancient Nubia (c. 1200BC)
- (2014) Michaela Binder et al. PLoS One
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis
- (2013) Nicole Beauchemin et al. CANCER AND METASTASIS REVIEWS
- Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?
- (2013) J. Maher et al. CANCER RESEARCH
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA
- (2012) Li Peng et al. PLoS One
- Strategies for extended serum half-life of protein therapeutics
- (2011) Roland E Kontermann CURRENT OPINION IN BIOTECHNOLOGY
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients
- (2011) Su Ning et al. MOLECULAR BIOLOGY REPORTS
- Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action
- (2010) Franziska Hirschhaeuser et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective
- (2010) Ruchi Saxena et al. MEDICINAL RESEARCH REVIEWS
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
- (2009) Hirofumi Shirakawa et al. CANCER SCIENCE
- Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma
- (2009) Alexei V. Salnikov et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Evolving novel anti-HER2 strategies
- (2009) Kellie L Jones et al. LANCET ONCOLOGY
- Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
- (2009) Sebastian Mannweiler et al. PATHOLOGY & ONCOLOGY RESEARCH
- Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
- (2008) M. Amann et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started